文献速递白血病

特异且可靶向的微环境相互作用影响伊马替尼耐药的慢性髓性白血病

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia.
PubMed 文献 · Leukemia · 2020-05-21

研究利用逆转录病毒转导/移植模型及人细胞系,重现TKI耐药导致的加速病程,发现BCR-ABL1T315I阳性伊马替尼耐药白血病细胞在龛定位及特异性龛相互作用上不同于BCR-ABL1原生细胞,涉及整合素β3/ILK通路及纤连蛋白沉积;纤连蛋白或ILK抑制剂治疗分别使异种及同种小鼠移植模型中BCR-ABL1T315I+ CML肿瘤负荷呈下降趋势并显著延长生存。

要点

  • BCR-ABL1T315I+伊马替尼耐药细胞在龛定位和特异性龛相互作用上不同于BCR-ABL1原生细胞。
  • 整合素β3/ILK通路及纤连蛋白沉积与上述差异相关。
  • 纤连蛋白或ILK抑制剂可延长BCR-ABL1T315I+ CML小鼠生存。

核心结论

  • BCR-ABL1T315I+细胞通过整合素β3/ILK介导的信号通路与ECM蛋白相互作用,差异且特异地影响白血病进展。
  • 通过调节ECM靶向龛可能是此情形下可考虑的一种可行治疗策略。

研究设计与样本

  • 使用CML的逆转录病毒转导/移植模型和人细胞系,重现TKI耐药的加速病程。
  • 在多种模型中比较鼠源和人源伊马替尼耐药BCR-ABL1T315I+白血病细胞与BCR-ABL1原生细胞。
  • 在异种和同种小鼠移植模型中分别用纤连蛋白或ILK抑制剂治疗BCR-ABL1T315I+ CML小鼠。

主要发现

  • 鼠源和人源伊马替尼耐药BCR-ABL1T315I+白血病细胞在龛定位和特异性龛相互作用上不同于BCR-ABL1原生细胞。
  • 整合素β3、ILK及其在ECM蛋白纤连蛋白沉积中的作用被牵涉为这些差异的原因。
  • 用纤连蛋白治疗的异种移植模型和用ILK抑制剂治疗的同种移植模型中,BCR-ABL1T315I+ CML小鼠肿瘤负荷呈下降趋势,生存显著延长。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy resistance in leukemia may be due to cancer cell-intrinsic and/or -extrinsic mechanisms. Mutations within BCR-ABL1, the oncogene giving rise to chronic myeloid leukemia (CML), lead to resistance to tyrosine kinase inhibitors (TKI), and some are associated with clinically more aggressive disease and worse outcome. Using the retroviral transduction/transplantation model of CML and human cell lines we faithfully recapitulate accelerated disease course in TKI resistance. We show in various models, that murine and human imatinib-resistant leukemia cells positive for the oncogene BCR-ABL1T315I differ from BCR-ABL1 native (BCR-ABL1) cells with regards to niche location and specific niche interactions. We implicate a pathway via integrin β3, integrin-linked kinase (ILK) and its role in deposition of the extracellular matrix (ECM) protein fibronectin as causative of these differences. We demonstrate a trend towards a reduced BCR-ABL1T315I+ tumor burden and significantly prolonged survival of mice with BCR-ABL1T315I+ CML treated with fibronectin or an ILK inhibitor in xenogeneic and syngeneic murine transplantation models, respectively. These data suggest that interactions with ECM proteins via the integrin β3/ILK-mediated signaling pathway in BCR-ABL1T315I+ cells differentially and specifically influence leukemia progression. Niche targeting via modulation of the ECM may be a feasible therapeutic approach to consider in this setting.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kumar R, Pereira RS, Zanetti C, et al. Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia. 2020. PMID: 32439895. doi:10.1038/s41375-020-0866-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。